serum institute of india news


Latest from serum institute of india

Pune-based Serum Institute to soon start Phase I & II trials of dengue vaccine in India

The Phase 1 and Phase 2 study of Dengusiil in India will be conducted on 45 adults of 18 years and above and 75 children of 2 years of age and above and less than (<) 18 years of age

After completion of the Phase 1/2 study, the Phase 3 study will be approved. (HT)
Updated on Nov 27, 2023 05:08 AM IST
ByVicky Pathare

Serum Institute founder Cyrus Poonawalla suffers cardiac arrest, undergoes angioplasty

Cyrus Poonawalla, chairman of Serum Institute of India, suffered a mild cardiac arrest and underwent angioplasty. He is recovering and will be discharged soon.

Cyrus Poonawalla, chairman and managing director, Serum Institute of India, was admitted at Ruby Hall Clinic on Friday early morning. (HT FILE PHOTO)
Updated on Nov 17, 2023 10:37 PM IST
ByVicky Pathare

Serum’s Cervavac vaccine for cervical cancer now in pvt hosps

Cervavac vaccine to fight cervical cancer has been developed and manufactured by the Pune-based Serum Institute of India (SII)

FILE PHOTO: A research scientist works inside a laboratory of India's Serum Institute. Cervavac vaccine to fight cervical cancer has been developed and manufactured by the Pune-based Serum Institute of India (SII). (REUTERS (PIC FOR REPRESENTATION))
Updated on Jul 18, 2023 12:54 AM IST
ByVicky Pathare

SII’s multivalent meningococcal meningitis vaccine gets WHO prequalification

It is also the only vaccine that prevents meningitis caused by meningococcal group X, a pathogen increasingly implicated in meningitis outbreaks in Africa

The vaccine protects against meningococcal serogroups A, C, W, Y, and X. (HT file image)
Updated on Jul 12, 2023 06:01 PM IST

RIL tops list of Indian companies, Serum Institute first among unlisted: Report

The Top 10 companies in India hold ₹71.5 lakh crore, accounting for 37% of GDP. 7 of them are headquartered in Mumbai. Here is the list:

Reliance Industries Limited's Mukesh Ambani (Left) and Serum Institute of India's Adar Poonawalla
Published on Jun 20, 2023 05:58 PM IST

HC restrains 2 influencers from posting defamatory content against SII, Covishield

The Bombay High Court has restrained two social media influencers from posting defamatory content about Serum Institute of India, its CEO and their Covishield product in an interim application filed by SII in a defamation suit against the influencers. The court directed Yohan Tengra and Ambar Kori to remove the content from Twitter and YouTube. The SII claims the content posted by the duo about multiple deaths being due to the side effects of the vaccine was not only targeted at SII but also its CEO, and sought directions to Twitter and YouTube to take down defamatory content.

HT Image
Updated on Jun 06, 2023 01:03 AM IST

Bombay HC restrains activists from posting defamatory content on SII, Covishield

The order was passed in an interim application filed by SII in a defamation suit seeking ₹100 crore in damages from social media influencers Yohan Tengra and Ambar Kori for allegedly posting objectionable content regarding Covishield

Serum Institute of India chief executive officer Adar Poonawalla. (File)
Updated on Jun 05, 2023 03:28 PM IST

ED attaches Zavaray Soli Poonawalla’s assets worth 41.64 crore in Worli

Enforcement Directorate seizes properties worth INR 41.64 crore belonging to Zavaray Soli Poonawalla and family over foreign exchange violation probe linked to Panama Papers.

Mumbai, February 22, 2015 : Behroze and Zavaray Poonawalla at the 26th Poonawalla Breeders Multi-Million (PBMM), race in Mumbai. (HT Photo) (Hindustan Times)
Updated on May 09, 2023 12:50 AM IST
ByAbhishek Sharan, Mumbai

‘Fema violation’ case: ED seizes 41.64cr assets of Pune bizman

The agency alleged that Zavareh Soli Poonawalla and his family members were accused of misuse of the Liberalised Remittance Scheme under the provisions of the Foreign Exchange Management Act.

A statement issued by the ED said it has “seized three immovable properties located at Ceejay house, Worli, Mumbai, worth <span class='webrupee'>₹</span>41.64 crore under the provisions of FEMA in its probe against Zavareh Soli Poonawalla and his family members”. (HT)
Updated on May 09, 2023 12:34 AM IST
By, New Delhi

UK Investment Min inaugurates British Trade office in Pune

According to a press release released by the British Deputy High Commission, India remains a priority market for the UK

PM Modi had visited city-based SERUM institute back in 2021. (HT PHOTO)
Updated on Apr 28, 2023 11:29 PM IST

Serum Institute of India to produce 5mn Covishield doses in two months

SII has made available five to six million Covovax doses even as the demand for it is still almost zero. We will produce the same amount of Covishield doses in the next two to three months, said Adar Poonawalla

Adar Poonawalla, chief executive officer of Serum Institute of India (SII). (HT PHOTO)
Updated on Apr 22, 2023 11:01 PM IST

WATCH: SII chief Adar Poonawalla on vaccine availability, current Covid strain

SII chief Adar Poonawalla on Saturday said that the current Covid strain is not severe and the company has produced five to six million doses of Covovax.

SII chief executive officer Adar Poonawalla.
Published on Apr 22, 2023 03:08 PM IST

India's Serum Institute resumes Covishield production as Covid cases surge

SII CEO Adar Poonawalla says Covishield manufacturing has resumed, 6M Covovax booster doses ready, and manufacturers are ready but no demand yet.

Adar Poonawalla, CEO of Serum Institute of India (HT FILE PHOTO)
Published on Apr 12, 2023 05:38 PM IST
PTI | | Posted by Animesh Chaturvedi

Serum institute seeks to add Covovax on CoWIN portal as booster dose for adults

Last month, COVID-19 Working Group also recommended to the health ministry inclusion of Covovax on the CoWIN portal as a heterologous booster dose for adults.

The letter was written by Prakash Kumar Singh, Director, Serum Institute of India (SII) on March 27, they said.(HT_PRINT)
Published on Apr 03, 2023 08:10 PM IST

Oxford, Serum initiative: Anti-malaria vaccine’s Phase 3 trials conclude

The R21 malaria vaccine, which is also known as Matrix-M, was designed at the Jenner Institute, University of Oxford, which collaborated with SII in 2020 to manufacture and develop the jab for large-scale supply.

According to WHO, malaria is a life-threatening disease caused by Plasmodium parasites that are transmitted to people through the bites of infected female Anopheles mosquitoes.
Published on Dec 06, 2022 08:33 AM IST
By, New Delhi

Serum Institute Whatsapp duping case: Seven held from various states

As per the First Information Report registered with Bundgarden police station in the second week of September, the accused had used Poonawalla's image in a Whatsapp account and sent messages about money transfer to Satish Deshpande, one of the directors of the firm.

Serum Institute of India CEO Adar Poonawalla.
Published on Nov 25, 2022 07:32 PM IST

SII's Adar Poonawalla expects Omicron-specific vaccine in 6 months: Report

Adar Poonawalla's statement came even as the UK became the first country to authorise an updated version of Moderna's Covid-19 vaccine that includes protection against the Omicron variant.

Adar Poonawalla, CEO of Serum Institute of India (SII), the world's biggest vaccine maker.(REUTERS file)
Published on Aug 15, 2022 11:36 PM IST
By, New Delhi

Monkeypox: As India sees rise in cases, what Adar Poonawalla said about vaccine

India has so far reported eight cases of monkeypox, of which five have been from Kerala and three from Delhi. Of the five patients in Kerala, one succumbed to the disease on July 30, making it India's first monkeypox fatality.

Adar Poonawalla, chief executive officer of Serum Institute of India Ltd. (Bloomberg)
Published on Aug 02, 2022 05:41 PM IST
Written by Sharangee Dutta | Edited by Aniruddha Dhar, New Delhi

Serum institute seeks government nod to export Covovax to the US

SII manufactures Covovax under a license from the vaccine’s developer, US-based Novavax. The export version of the vaccine is called Nuvaxovid and has been dispatched to New Zealand, Netherlands, Australia and Indonesia, where a total of at least 100 million doses have been sent.

SII chief executive officer Adar Poonawalla. (REUTERS)
Published on Jul 01, 2022 03:16 AM IST
By, New Delhi

Govt panel recommends market authorisation for Serum's cervical cancer vaccine

Cervical cancer in India ranks as the second most frequent cancer among women between 15 and 44 years of age.

The SII is also learnt to have made a presentation before the working group of HPV constituted separately by the NTAGI to review the data and usefulness of this vaccine last Wednesday.( representative image)
Published on Jun 15, 2022 10:37 PM IST

Covovax gets govt nod for 12-18 age group at private centres

On April 29, the National Technical Advisory Group on Immunisation (NTAGI)--the government’s technical panel--recommended inclusion of Covovax in the vaccination programme for children aged 12 and above.

Currently, while Covishield is available for all adults, Bharat Biotech’s Covaxin is available for those aged 15 and above. Corbevax is being used for children in the 12-15 age group (HT FILE)
Published on May 03, 2022 11:37 PM IST

'Covovax now available for children in India', says Adar Poonawalla, hails Modi

Serum Institute of India (SII) director for government and regulatory affairs Prakash Kumar Singh had written to the Centre recently requesting for Covovax's inclusion in the immunisation drive for children aged 12 to 17 years.

Adar Poonawalla’s Serum Institute of India locally manufactures the Oxford-AstraZeneca Covid vaccine under the brand name Covishield.(Reuters file)
Updated on May 10, 2022 07:57 PM IST
By, New Delhi

Made in India Covid vaccines better than Pfizer, Moderna: SII's Adar Poonawalla

Speaking to ANI, Poonawalla said, "The Covid-19 vaccines which have been made in India are providing more protection against the disease than mRNA vaccines like Pfizer and Moderna."

On being asked about the export of the Covishield Covid-19 vaccine, Adar Poonawalla
Published on Apr 13, 2022 04:22 PM IST

Covishield booster shots to be priced at 600 plus taxes: Adar Poonawalla

Covovax - which has not been formally announced as a booster shot, will be priced around ₹900 plus taxes, once approved. The vaccine is currently being used to inoculate adults and those in the 12-17 age group in emergency situations.

Covishield has been manufactured by Pune-based Serum Institute of India, which is the world's largest vaccine maker.(Reuters)
Updated on Apr 08, 2022 06:54 PM IST
By | Written by Sharangee Dutta, New Delhi

Can’t disclose data on trials: Vaccine makers to Supreme Court

Submitting its reply to Puliyel’s petition in November last, the central drugs standard control organization (CDSCO) said that entertaining such a petition would harm public interest.

A student receives a dose of a Covid vaccine in Noida. (HT photo/Sunil Ghosh)
Updated on Mar 23, 2022 05:04 AM IST

Give full authorisation to Covishield: Serum Institute of India

Serum Institute of India locally manufactures the Oxford-AstraZeneca Covid-19 vaccine under the brand name Covishield.

Ranchi, Dec 28 (ANI): A beneficiary receives a dose of the COVID-19 vaccine during a door-to-door vaccination programme, at Deoghar, in Ranchi on Tuesday. (ANI Photo) (Somnath Sen)
Updated on Dec 31, 2021 11:07 PM IST

Serum Institute of India applies for full approval of Covishield Covid vaccine

Serum Institute, which produces AstraZeneca's Covid-19 vaccine under the brand name Covishield, has supplied more than 1.25 billion doses of the shot in India.

Serum Institute, which is also the world's biggest vaccine maker, was granted approval for emergency use of Covishield in India at the beginning of the year.(Reuters)
Published on Dec 31, 2021 01:48 PM IST
Reuters | , Bengaluru

Covovax gets WHO’s nod for emergency use

SII has the license to produce over two billion doses of the vaccine

Covovax is part of the WHO-led Covax facility. SII began stockpiling doses in the summer and a Union health ministry assessment in June said the government expects 200 million doses of the vaccine to be available by December.(HT File)
Published on Dec 18, 2021 02:14 AM IST
By, Hindustan Times, New Delhi

Vaccine maker SII pledges $66 million to Oxford University

The investment was made through the Indian company's Serum Life Sciences unit, Oxford University said on Wednesday.

The research building would be named after Serum's billionaire owners, the Poonawalla family. The pledge builds on the collaboration between Oxford University, AstraZeneca and SII(Reuters)
Published on Dec 15, 2021 05:50 AM IST
Reuters |

Omicron: Will India allow booster dose? Here's what central expert panel said

The Pune-based SII had earlier on December 1 requested the DCGI to authorise Covishield as a booster dose, citing the emergence of new coronavirus variants in the country and an adequate stock of vaccines to tackle that growing concern.

More than 60 countries across the world have already authorised booster doses of the Covid-19 vaccine, said the central government in a written reply to Parliament this week. (Representational Image / AP)
Published on Dec 11, 2021 07:53 AM IST
Written by Joydeep Bose | Edited by Meenakshi Ray, Hindustan Times, New Delhi
  • 1
  • 2
  • 3
  • ...
Story Saved
Live Score
Saved Articles
My Reads
Sign out
New Delhi 0C
Saturday, December 02, 2023
Start 14 Days Free Trial Subscribe Now
Register Free and get Exciting Deals